CRISPR Therapeutics (CRSP) Says EPO to Grant CRISPR/Cas Gene Editing Patent

March 28, 2017 8:06 AM EDT Send to a Friend
CRISPR Therapeutics (NASDAQ: CRSP) reported that the European Patent Office (EPO) has announced its intention to grant a patent broadly ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login